Symbol="TCRT"
AssetType="Common Stock"
Name="Alaunos Therapeutics Inc"
Description="Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas."
CIK="1107421"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="108282000"
EBITDA="-30559000"
PERatio="None"
PEGRatio="None"
BookValue="0.123"
DividendPerShare="0"
DividendYield="0"
EPS="-0.16"
RevenuePerShareTTM="0.013"
ProfitMargin="0"
OperatingMarginTTM="-11.4"
ReturnOnAssetsTTM="-0.312"
ReturnOnEquityTTM="-0.966"
RevenueTTM="2922000"
GrossProfitTTM="-19596000"
DilutedEPSTTM="-0.16"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.31"
AnalystTargetPrice="3.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="50.84"
PriceToBookRatio="5.02"
EVToRevenue="51.16"
EVToEBITDA="-4.306"
Beta="0.184"
num_52WeekHigh="4.01"
num_52WeekLow="0.41"
num_50DayMovingAverage="0.505"
num_200DayMovingAverage="0.682"
SharesOutstanding="240627000"
DividendDate="None"
ExDividendDate="None"
symbol="TCRT"
open="0.43"
high="0.45"
low="0.43"
price="0.44"
volume="339562.00"
latest_trading_day="2023-07-27"
previous_close="0.44"
change="0.01"
change_percent="1.2832%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="74"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="26"
Volume_recent_avg="579062"
Change_recent_avg="-0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-1.12"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="26"
Aroon_momentum_negative="74"
image_negative_thumbnail_id_1="107"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0069.jpeg"
image_negative_thumbnail_id_2="1125"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0158.jpeg"
image_neutral_thumbnail_id_1="532"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0067.jpeg"
image_neutral_thumbnail_id_2="527"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0072.jpeg"
image_positive_thumbnail_id_1="633"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0075.jpeg"
image_positive_thumbnail_id_2="644"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0064.jpeg"
image_professor_thumbnail_id_1="1175"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
image_professor_thumbnail_id_2="1182"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
